Genmab HexaBody - Model CD38 (GEN3014) - Novel Human Monoclonal Antibody

GEN3014 (HexaBody^®-CD38) is a novel human CD38 monoclonal antibody incorporating Genmab’s HexaBody^® technology. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech Inc. to develop and commercialize HexaBody^®-CD38. In preclinical models of hematological malignancies, HexaBody^®-CD38 demonstrated enhanced complement-dependent cytotoxicity and potent anti-tumor activity^.